Harvard Bioscience Inc. Release: Five-Year Follow-Up of World’s First Regenerated Trachea Transplant Published in The Lancet

HOLLISTON, Mass., Oct. 23, 2013 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO) and Harvard Apparatus Regenerative Technology (Nasdaq:HARTV) jointly announce that five years after a 30-year-old woman was implanted with the world's first tissue-engineered trachea grown in a bioreactor she lives complication-free, according to an article published October 23 in The Lancet.

Help employers find you! Check out all the jobs and post your resume.